盛 君,陸進明,強孚勇,毛桐俊
(皖南醫(yī)學(xué)院第一附屬醫(yī)院 弋磯山醫(yī)院 風(fēng)濕免疫科,安徽 蕪湖 241001)
?
·臨床醫(yī)學(xué)·
絕經(jīng)后女性類風(fēng)濕關(guān)節(jié)炎患者骨折風(fēng)險評估工具的預(yù)測價值
盛君,陸進明,強孚勇,毛桐俊
(皖南醫(yī)學(xué)院第一附屬醫(yī)院 弋磯山醫(yī)院風(fēng)濕免疫科,安徽蕪湖241001)
【摘要】目的:應(yīng)用世界衛(wèi)生組織骨折風(fēng)險評估工具(FRAX)對絕經(jīng)后女性類風(fēng)濕關(guān)節(jié)炎(RA)患者骨質(zhì)疏松性骨折風(fēng)險進行評估。方法:收集2012~2013年門診及住院的119例絕經(jīng)女性RA患者的相關(guān)臨床資料及實驗室指標,使用美國GE-lunar雙能X線骨密度儀對患者的腰椎及左側(cè)股骨頸的骨礦含量(BMD)進行測定,應(yīng)用FRAX中國模式計算受試患者未來10年髖部骨折風(fēng)險概率,采用SPSS 16.0軟件對結(jié)果進行分析比較。結(jié)果:119例RA患者中,年齡39~82歲,平均(58±15)歲,病程2個月~40年,中位數(shù)病程7年。骨量減少患者68例(57.1%),骨質(zhì)疏松患者32例(26.9%),自發(fā)性髖部骨折患者8例(6.7%);依據(jù)FRAX計算出未來10年髖部骨折概率0.1%~22%,按骨折風(fēng)險概率分組,高危組與低危組的年齡、體質(zhì)量指數(shù)、血清白蛋白水平及骨密度值相比,差異有統(tǒng)計學(xué)意義(P<0.05),在病程、絕經(jīng)年齡、DAS28評分、ESR、CRP、RF、抗CCP抗體方面比較差異無統(tǒng)計學(xué)意義(P>0.05)。線性相關(guān)分析顯示:髖部骨質(zhì)疏松性骨折風(fēng)險概率與年齡、服用激素呈正相關(guān)關(guān)系,與體質(zhì)量指數(shù)、骨密度呈負相關(guān)關(guān)系。Logistic回歸分析顯示:年齡大[OR=1.140,P=0.000,95%CI(1.019,1.193)]、體質(zhì)量指數(shù)低[OR=0.201,P=0.006,95%CI(0.064,0.633)],服用糖皮質(zhì)激素[OR=4.941,P=0.002,95%CI(1.770,13.796)]及股骨頸骨密度值低[OR=0.927,P=0.005,95%CI(0.867,0.986)]的患者發(fā)生髖部10年骨質(zhì)疏松性骨折風(fēng)險率增加。結(jié)論:年齡大、體質(zhì)量指數(shù)低,服用激素及股骨頸骨密度值低的患者發(fā)生髖部10年骨質(zhì)疏松性骨折風(fēng)險率增加。由于FRAX應(yīng)用中未包括RA疾病狀態(tài)和病程長短,提示FRAX尚不能全面評估絕經(jīng)女性RA患者骨質(zhì)疏松性骨折風(fēng)險。
【關(guān)鍵詞】類風(fēng)濕關(guān)節(jié)炎;骨質(zhì)疏松;骨折風(fēng)險評估工具(FRAX);絕經(jīng)女性
【DOI】10.3969/j.issn.1002-0217.2016.03.006
類風(fēng)濕關(guān)節(jié)炎(rheumatoid arthritis,RA)是多關(guān)節(jié)受累的慢性炎癥性、自身免疫性疾病,骨與關(guān)節(jié)損傷為本病的主要臨床表現(xiàn),隨病情進展可導(dǎo)致局部骨侵蝕和全身骨丟失,進而導(dǎo)致骨質(zhì)疏松(osteoporosis,OP)的發(fā)生。RA患者骨量減少和OP的發(fā)生率顯著高于正常人群,在繼發(fā)性O(shè)P的病因中占重要地位,絕經(jīng)老年女性這種趨勢加重。骨折風(fēng)險評估工具(fracture risk assessment,FRAX)是一種應(yīng)用臨床危險因素來評估每一位個體發(fā)生OP性骨折絕對風(fēng)險的工具,能夠?qū)€體進行未來10年OP性骨折風(fēng)險評估。本研究探討FRAX工具在預(yù)測絕經(jīng)后女性RA患者骨折風(fēng)險評估中的意義,以期提供對診斷和治療有益的臨床數(shù)據(jù)。
1資料與方法
1.1一般資料收集2012~2013年弋磯山醫(yī)院門診及住院的119例絕經(jīng)女性類風(fēng)濕關(guān)節(jié)炎患者,所有患者診斷均符合1987年美國風(fēng)濕病學(xué)會RA分類標準。入選患者排除長期服用雌激素、抗凝劑、有嚴重腎功能損壞、甲狀腺、甲狀旁腺等疾患,詳細記錄所有患者臨床一般資料(年齡、性別、身高、體質(zhì)量、既往骨折病史及部位、絕經(jīng)年齡、吸煙史、飲酒史、病程、服用抗風(fēng)濕病藥物及激素史及父母髖部骨折史),并記錄患者發(fā)病時間、關(guān)節(jié)壓痛數(shù)、關(guān)節(jié)腫脹數(shù)及糖皮質(zhì)激素使用時間與劑量等。
1.2方法采用美國GE-lunnr雙能X線骨密度儀對患者腰椎及左側(cè)股骨頸的骨礦含量(BMD)進行測定并記錄,同時常規(guī)測定血常規(guī)、紅細胞沉降率(ESR)、C反應(yīng)蛋白(CRP)、類風(fēng)濕因子(RF)、抗環(huán)瓜氨酸肽抗體(抗CCP)水平。進入FRAX界面(http://shef.Ac.uk/FRAX/index.Htm),輸入各項數(shù)據(jù)應(yīng)用中國模式計算受試個體的未來10年髖部及主要骨質(zhì)疏松骨折的概率。判斷標準:≥3%為高危組,<3%為低危組。
2結(jié)果
2.1絕經(jīng)女性RA患者一般情況資料119例患者,年齡39~82歲,平均(58±15)歲,病程2月~40年,中位數(shù)病程7年,骨量減少患者68例(57.1%),骨質(zhì)疏松患者32例(26.9%),自發(fā)性髖部骨折患者8例(6.7%);具體數(shù)值見表1。
表1119例絕經(jīng)女性RA患者一般情況資料
項目數(shù)值年齡/(歲,x±s)58±15BMI/(kg/m2,x±s)21.5±4.6既往骨折史[n(%)]16(13.45)父母髖部骨折史[n(%)]6(5.04)目前抽煙行為[n(%)]5(4.20)每日酒精攝入量≥3個單位[n(%)]2(1.68)病程/月 ≤6月[n(%)]10(8.4) 6月~2年[n(%)]30(25.2) >2年[n(%)]79(66.4)激素使用(n=96) ≤6個月[n(%)]13(13.5) 6月~2年[n(%)]27(28.2) >2年[n(%)]56(58.3)骨量正常[n(%)]19(16.0)骨量減少[n(%)]68(57.1)骨量疏松[n(%)]32(26.9)髖部骨折[n(%)]8(6.7)
注:1個酒精單位量因各國定量標準有所不同,范圍從8~10 g不等。相當(dāng)于一杯標準啤酒(285 mL),一個量度烈酒(30 mL),一個中杯葡萄酒(120 mL),或者一個量度的開胃酒(60 mL)。
2.2髖部骨質(zhì)疏松性骨折概率高危組與低危組相關(guān)因素比較根據(jù)FRAX工具計算未來10年髖部骨質(zhì)疏松性骨折概率0.1%~22%,其中高危組(骨折概率≥3%)69例,低危組(骨折概率<3%)50例,兩組臨床及實驗室指標相比見表2。
表2絕經(jīng)后RA患者髖部骨質(zhì)疏松性骨折風(fēng)險概率高危組與低危組臨床及實驗室指標比較
項目高危組(n=69)低危組(n=50)t/Z值P值年齡/(歲,x±s)65±958±64.804<0.001絕經(jīng)年齡/(歲,x±s)49±450±30.0120.991BMI/(kg/m2,x±s)20.0±4.124.0±7.22.6540.002病程/[年,M(Q)]11.0(11.0)6.5(12.0)0.0190.985壓痛關(guān)節(jié)數(shù)/[個,M(Q)]10.0(6.0)6.0(3.3)1.0770.281腫脹關(guān)節(jié)數(shù)/[個,M(Q)]12.0(9.0)5.0(4.6)1.1790.238激素使用人數(shù)58/6938/5051.860<0.001DAS28(x±s)5.3±1.74.9±1.61.1690.245ESR/[mm/1h,M(Q)]71.0(25.0)60.0(22.1)0.9930.321CRP/[mg/L,M(Q)]28.2(21.9)19.2(17.0)0.9770.328RF/[IU/mL,M(Q)]197.0(318.1)125.5(276.1)0.7190.472抗CCP/[RU/mL,M(Q)]282.0(762.6)329.5(769.6)0.0050.996ALB/(g/L,x±s)30.8±6.536.9±7.32.6240.004骨密度/(g/cm2,x±s)0.63±0.750.80±0.110.790<0.001
2.3髖部骨質(zhì)疏松性骨折風(fēng)險概率與臨床及實驗室指標相關(guān)性線性相關(guān)分析顯示,髖部骨質(zhì)疏松性骨折風(fēng)險概率與年齡、是否服用激素呈正相關(guān)關(guān)系,與體質(zhì)量指數(shù)、骨密度呈負相關(guān)關(guān)系,而與病程、絕經(jīng)年齡、DAS28評分、ESR、CRP、RF、抗CCP抗體、ALB水平等均無明顯相關(guān)性,見表3。
2.4絕經(jīng)女性RA患者髖部骨質(zhì)疏松性骨折風(fēng)險概率的多元回歸分析根據(jù)預(yù)測的髖部十年骨質(zhì)疏松性骨折風(fēng)險率,以高危低危作為兩項分類應(yīng)變量(0=低危,1=高危),以年齡、體質(zhì)量指數(shù)、骨密度值、是否服用激素(0=未使用,1=使用)作為自變量,采用Logistic回歸進行分析,結(jié)果顯示隨著年齡增加及服用糖皮質(zhì)激素,發(fā)生髖部骨質(zhì)疏松性骨折風(fēng)險增加,而較高的BMI和骨密度值可以降低髖部骨質(zhì)疏松性骨折風(fēng)險,具體見表4。
表3絕經(jīng)后RA患者未來10年髖部骨質(zhì)疏松性骨折風(fēng)險概率與臨床及實驗室指標相關(guān)性
項目rP年齡0.414<0.001病程-0.0230.803BMI-0.4700.000使用激素0.2300.031腫脹關(guān)節(jié)數(shù)0.0610.510壓痛關(guān)節(jié)數(shù)0.0390.675DAS28評分0.0240.794ESR0.1230.182CRP0.1800.05RF0.0550.550抗CCP抗體0.0170.852骨密度值-0.811<0.001ALB水平0.0410.660
表4髖部骨質(zhì)疏松性骨折風(fēng)險率影響因素的Logistic回歸分析
βSEWaldχ2POROR95%CI年齡0.1310.02333.3720.0001.140(1.0190,1.193)BMI-1.6060.5877.5000.0060.201(0.064,0.633)骨密度值-0.0790.0288.4130.0050.927(0.867,0.986)服用激素1.5980.5249.3000.0024.941(1.770,13.796)
3討論
RA是以多關(guān)節(jié)受累為主的自身免疫性疾病,發(fā)病率高。OP是一種骨量減少及骨組織結(jié)構(gòu)改變伴骨脆性增加而易導(dǎo)致骨折的全身性骨骼疾病。RA由于一些炎癥性細胞因子的作用,以及糖皮質(zhì)激素藥物等影響,RA患者OP發(fā)生率高,骨折風(fēng)險增加[1-2]。Hafez EA等對病程在6個月內(nèi)RA患者進行骨密度測定,結(jié)果僅36.7%患者骨量正常,50%骨量減少,13.3%骨質(zhì)疏松,OP患者疾病活動程度高,并且更易于發(fā)生骨破壞[3]。而絕經(jīng)期女性RA患者加重了骨質(zhì)疏松的趨勢,Haugeberg G等[4]調(diào)查了394例挪威女性RA患者,結(jié)果顯示OP的發(fā)病率是正常人群的兩倍。 我們的研究結(jié)果顯示骨量減少患者68例(57.1%),OP患者32例(26.9%),自發(fā)性髖部骨折患者8例(6.7%),均顯著高于RA人群,證實絕經(jīng)女性RA患者存在骨質(zhì)疏松和骨量減少。
FRAX是一種應(yīng)用臨床危險因素來評估每一位個體發(fā)生OP性骨折絕對風(fēng)險的工具,能夠?qū)€體進行未來10年OP性骨折風(fēng)險評估。RA患者的骨折風(fēng)險較正常人增加,而使用FRAX可以篩選出高危RA人群,并對其進行診治[5]。 在我們調(diào)查研究中根據(jù)FRAX工具計算未來十年髖部OP骨折概率0.1%~22%,其中高危組(骨折概率≥3%)69例,本組研究顯示高危組患者年齡較大,體質(zhì)量指數(shù)、血清白蛋白水平及骨密度值低,但高危組與低危組在病程、絕經(jīng)年齡、壓痛關(guān)節(jié)數(shù)、腫脹關(guān)節(jié)數(shù)、DAS28評分、ESR、CRP、RF、抗CCP抗體等方面比較差異無統(tǒng)計學(xué)意義。國內(nèi)外研究表明,骨質(zhì)疏松性骨折發(fā)生率在50歲以后隨年齡增加按指數(shù)比例增加[6],我們研究也表明,年齡偏大的RA患者發(fā)生骨質(zhì)疏松性骨折風(fēng)險概率明顯增高,骨折發(fā)生危險與年齡明顯相關(guān)。Rorsblad等[7]對骨密度減少的絕經(jīng)后活動性類風(fēng)濕關(guān)節(jié)炎婦女進行研究,表明低體質(zhì)量與骨密度下降密切相關(guān)。在我們研究中也顯示出體質(zhì)量指數(shù)低患者骨密度值低,骨折風(fēng)險高,與之相符合。糖皮質(zhì)激素在RA中作用復(fù)雜,一項縱向研究表明,RA患者應(yīng)用糖皮質(zhì)激素能顯著改善RA患者關(guān)節(jié)癥狀,但會降低骨量,增加骨折危險性[8],但另有研究顯示未經(jīng)糖皮質(zhì)激素治療的RA患者骨組織形態(tài)學(xué)研究顯示骨形成減少,RA活動持續(xù)2年以上的患者各部位骨密度減少5%~10%[9],提示RA患者出現(xiàn)骨質(zhì)疏松與疾病本身的炎癥有關(guān)??赡苡捎谔瞧べ|(zhì)激素可以阻止炎癥進而影響骨代謝。本研究顯示高危組患者激素使用頻率高于低危組,相關(guān)性分析表明自發(fā)性骨折危險傾向與使用激素密切相關(guān)。
有研究表明RA的炎癥狀態(tài)、疾病的高活動性是導(dǎo)致骨代謝異常、骨破壞、關(guān)節(jié)侵蝕、全身性O(shè)P和脆性骨折發(fā)生率增加的根本原因[10]。但Weiss等[2]的研究認為,疾病活動與RA骨質(zhì)疏松的發(fā)生并無明顯相關(guān),即使處于疾病穩(wěn)定期的RA患者仍存在骨量丟失,即臨床緩解與結(jié)構(gòu)破壞相分離的現(xiàn)象。我們研究結(jié)果顯示,髖部骨質(zhì)疏松性骨折風(fēng)險率與年齡、體質(zhì)量指數(shù)、骨密度值及是否使用激素相關(guān),而與病程、絕經(jīng)年齡、DAS28評分、ESR、CRP、RF、抗CCP抗體等無明顯相關(guān)性。研究顯示RF滴度高者易發(fā)生骨侵蝕,RA患者的低骨量與疾病的活動性呈正相關(guān)[11],但FRAX軟件應(yīng)用中未包括RF、CRP、ESR及抗CCP抗體等反映RA的疾病活動的相關(guān)因子,提示FRAX可能不能全面評估RA患者骨質(zhì)疏松性骨折風(fēng)險概率 。
本研究對FRAX在絕經(jīng)女性RA骨質(zhì)疏松中的應(yīng)用進行了初步的探討,對有高危風(fēng)險的患者進行相應(yīng)的風(fēng)險干預(yù)治療,但FRAX軟件應(yīng)用中未包括RF、CRP、ESR及抗CCP抗體等反映RA的疾病活動的相關(guān)因子,F(xiàn)RAX對于進一步指導(dǎo)RA合并骨質(zhì)疏松臨床意義還需要在今后的工作中不斷去探索。
【參考文獻】
[1]AIZER J,REED G,ONOFREI A,etal.Predictors of bone density testing in patients with rheumatoid arthritis[J].Rheumatol Int,2009,29(8):897-905.
[2]WEISS RJ,WICK MC,AEKERMANN PW,etal.Increased fracture risk in patients with heumatic disorders and other inflammatory diseases:a case-control study with 53108 patients with fracture[J].J Rheumatol,2010,37(11):2247-2250.
[3]HAFEZ EA,MANSOUR HE,HAMZA SH,etal.Bone mineral density changes in patients with recent-onset rheumatoid arthritis[J].Clin Med Insights Arthritis Musculoskelet Disord,2011,4:87-94.
[4]HAUGEBERG G,UHLIG T,FALCH JA,etal.Bone mineral density and frequency of osteoporosis in famale patients with theumatoid arthritis:resulis from 394 patients in the Oslo County Rheumatoid Arthritis register[J].Arthritis Rheum,2000,43(3):522-530.
[5]YOON J,KWON SR,LIM MJ,etal.A Comparison of Three Different guidelines for osteoporosis treatment in patients with rheumatoid arthritis in Korea[J].Korean J Intern Med,2010,25(4):436-446.
[6]COURIS CM,CHAPURLAT RD,KANIS JA,etal.FRAX probabilities and risk of major osteoporotic fracture in France[J].Osteopros Int,2012,23(9):2321-2327.
[7]FORSBLAD D′ELIA H,LARSEN A,WALTBRAND E,etal.Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis[J].Ann Rheum Dis,2003,62(7):617-623.
[8]CAPLAN L,HINES AE,WILLIAMS E,etal.An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis[J].Osteoporos Int,2011,22(1):305-315.
[9]BRAUN J,BUTTGEREIT F,DREHER R,etal.Recommendations for the Prevention and Treatment of Glucocorticoid-Induced osteoporosis:2001 update.American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis[J].Arthritis Rheum,2001,44(7):1496-1503.
[10]WIJBRANDTS CA,KLAASEN R,DIJKGRAAF MG,etal.Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy:arrest of boneloss[J].Ann Rheum Dis,2009,68(3):373-376.
[11]GOLDRING SR,GRAVALLESE EM.Mechanisms of bone loss in inflammatory arthritis:diagnosis and therapeutic implications[J].Arthritis Res,2000,2(1):33-37.
Clinical application of fracture risk assessment tool to predicting the osteoporotic fractures in postmenopausal women with rheumatoid arthritis
SHENG Jun,LU Jinming,QIANG Fuyong,MAO Tongjun
Department of Rheumatology,The First Affiliated Hospital of Wannan Medical College,Wuhu 241001,China
【Abstract】Objective:To assess the clinical value of Fracture Risk Assessment Tool(FRAX) recommended by World Health Organization (WHO) in predicting the risks of osteoporotic fractures in postmenopausal women with rheumatoid arthritis(RA).Methods:Clinical data and laboratory findings were obtained from 119 postmenopausal women with RA treated in our hospital on outpatient or inpatient basis between January 2012 and December 2013.All patients were measured for the bone mineral density(BMD) at the lumbar vertebra and left femoral neck with Dual-energy X-ray absorptiometry(DXA,GE Lunar Prodigy,US),and computed for the fracture risks at the hip in the following 10 years with FRAX model for Chinese women,by which patients were allocated to high risk and low risk group.Software SPSS(version 16.0) was used to analyze the results.Results:In 119 RA women,the ages ranged from 39 to 82 years,with average age of (58±15) years.Disease course was from 2 months to 40 years(mean 7 years).Reduced bone volume was seen in 68 cases(57.1%),osteoporosis in 32(26.9%) and spontaneous hip fracture in 8(6.7%).By FRAX screens,risks for hip fractures in the following decade were 0.1% to 22% in our cohort.The difference was significant between high and low risk groups regarding the ages,BMI,serum albumin level and ratio of bone density(P<0.05),yet not significant concerning the course of disease,age of menopause,Disease Activity Score-28(DAS28),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),rheumatoid factor(RF) and antibodies to cyclic citrullinated peptide(CCP)(P>0.05).Linear correlation analysis indicated that risks for hip fractures from osteoporosis were positively related to patient′s age and history of oral glucocorticoid,yet negatively to BMI and bone density.Logistic regression analysis demonstrated higher risks for osteoporotic hip fractures in following decade in women of older age[OR=1.140,P<0.001; 95% CI(1.019,1.193)],with lower BMI [OR=0.201,P=0.006; 95%CI(0.064,0.633)],history of glucocorticoid use [OR=4.941,P=0.002; 95% CI(1.770,13.796)] and lower femur density value[OR=0.927,P=0.005; 95% CI(0.867,0.986)].Conclusion:FRAX screens show that patients of older age,with lower BMI and history of oral glucocorticoid as well as decreased serum albumin level and femur density value are prone to spontaneous osteoporotic hip fractures in following 10-year periods.However,FRAX is incompetent for full assessment of the risks for postmenopausal women with RA because of some important clinical variables associated with RA state and course of the disease being not incorporated.
【Key words】rheumatoid arthritis; osteoporosis; Fracture Risk Assessment Tool; menopausal women
文章編號:1002-0217(2016)03-0226-04
基金項目:皖南醫(yī)學(xué)院弋磯山醫(yī)院三新項目(Y12032)
收稿日期:2015-10-05
作者簡介:盛君(1972-),女,主治醫(yī)師,(電話)15155361009,(電子信箱)shengjun0330@163.com.
【文獻標識碼】【中圖號】R 593.22;R 683A